|
At Entelos, the key to building PhysioLab platforms and using them for in silico R&D is the
Company’s top-down, outcome-focused approach.
Top-down modeling starts by identifying the clinical measures most characteristic of a particular
disease; for example, blood glucose and insulin levels and body weight in the case of the Metabolism
PhysioLab platform. This is followed by identifying the relevant physiological systems and components
involved in regulating these measures, then mathematically representing the functions and interactions
of relevant components using systems of ordinary nonlinear differential equations.
The platforms are designed, tested, and built using rigorous principles from the engineering
sciences that were developed for studying complex, integrated, and robust dynamic systems. In this
way, functions at the biochemical and cellular levels are mechanistically integrated and connected
to observable clinical outcomes, and the level of detail included in a model is driven by the
specific research challenges needing to be addressed.
Entelos' top-down approach and in silico methods complement traditional research, connecting
basic research results to clinical outcomes. This integrated disease knowledge, combined with a
biosimulation capability, allows for systematic and rapid drug testing, helping to overcome
traditional R&D difficulties by:
- Focusing on a drug's ultimate clinical impact
- Identifying and resolving uncertainties in the underlying biology
- Enabling R&D teams to do more decisive experiments and design better clinical trials much
earlier in the process
|
